Shahin Hajibandeh1, Shahab Hajibandeh1, Stavros A Antoniou2, Francesco Torella1, George A Antoniou3. 1. Liverpool Vascular and Endovascular Service, Royal Liverpool University Hospital, Liverpool, UK. 2. Department of General Surgery, University Hospital of Heraklion, University of Crete, Heraklion, Greece. 3. Department of Vascular and Endovascular Surgery, The Royal Oldham Hospital, Pennine Acute Hospitals NHS Trust, Manchester, UK antoniou.ga@hotmail.com.
Abstract
PURPOSE: To examine the role of left subclavian artery (LSA) revascularization in thoracic endovascular aortic repair (TEVAR) with LSA coverage. METHODS: A systematic search was conducted to identify all studies providing comparative outcomes with or without LSA revascularization for LSA occlusion during TEVAR. The search included MEDLINE, EMBASE, CINAHL, the Cochrane Central Register of Controlled Trials, the World Health Organization International Clinical Trials Registry, ClinicalTrials.gov, ISRCTN Register, and bibliographic reference lists. The primary outcome parameters were perioperative stroke, spinal cord ischemia (SCI), and mortality. Combined overall effect sizes were calculated using fixed effect or random effects models; results are reported as the odds ratio (OR) and 95% confidence interval (CI). RESULTS: Five observational studies reporting a total of 1161 patients were identified; 444 patients underwent LSA revascularization and the remaining 717 patients did not. LSA revascularization was associated with a similar risk of stroke (OR 0.70, 95% CI 0.43 to 1.14, p=0.15), SCI (OR 0.56, 95% CI 0.28 to 1.10, p=0.09), and mortality (OR 0.87, 95% CI 0.55 to 1.39, p=0.56) compared with no LSA revascularization. CONCLUSION: LSA revascularization was not found to significantly reduce neurologic complications or mortality in patients undergoing TEVAR with coverage of the LSA origin. Randomized clinical trials are required to elucidate the role of routine or selective LSA revascularization in these cases.
PURPOSE: To examine the role of left subclavian artery (LSA) revascularization in thoracic endovascular aortic repair (TEVAR) with LSA coverage. METHODS: A systematic search was conducted to identify all studies providing comparative outcomes with or without LSA revascularization for LSA occlusion during TEVAR. The search included MEDLINE, EMBASE, CINAHL, the Cochrane Central Register of Controlled Trials, the World Health Organization International Clinical Trials Registry, ClinicalTrials.gov, ISRCTN Register, and bibliographic reference lists. The primary outcome parameters were perioperative stroke, spinal cord ischemia (SCI), and mortality. Combined overall effect sizes were calculated using fixed effect or random effects models; results are reported as the odds ratio (OR) and 95% confidence interval (CI). RESULTS: Five observational studies reporting a total of 1161 patients were identified; 444 patients underwent LSA revascularization and the remaining 717 patients did not. LSA revascularization was associated with a similar risk of stroke (OR 0.70, 95% CI 0.43 to 1.14, p=0.15), SCI (OR 0.56, 95% CI 0.28 to 1.10, p=0.09), and mortality (OR 0.87, 95% CI 0.55 to 1.39, p=0.56) compared with no LSA revascularization. CONCLUSION: LSA revascularization was not found to significantly reduce neurologic complications or mortality in patients undergoing TEVAR with coverage of the LSA origin. Randomized clinical trials are required to elucidate the role of routine or selective LSA revascularization in these cases.
Authors: Rens R B Varkevisser; Nicholas J Swerdlow; Livia E V M de Guerre; Kirsten Dansey; Chun Li; Patric Liang; Christopher A Latz; Mathijs T Carvalho Mota; Hence J M Verhagen; Marc L Schermerhorn Journal: J Endovasc Ther Date: 2020-05-21 Impact factor: 3.487
Authors: Hamdy Awad; Mohamed Ehab Ramadan; Hosam F El Sayed; Daniel A Tolpin; Esmerina Tili; Charles D Collard Journal: Can J Anaesth Date: 2017-10-10 Impact factor: 5.063
Authors: Piotr Buczkowski; Mateusz Puślecki; Natalia Majewska; Tomasz Urbanowicz; Marcin Misterski; Robert Juszkat; Jerzy Kulesza; Bartosz Żabicki; Sebastian Stefaniak; Marcin Ligowski; Lukasz Szarpak; Marek Jemielity; Eva Rivas; Kurt Ruetzler; Bartłomiej Perek Journal: J Thorac Dis Date: 2019-06 Impact factor: 2.895
Authors: Piotr Buczkowski; Mateusz Puslecki; Sebastian Stefaniak; Robert Juszkat; Jerzy Kulesza; Bartłomiej Perek; Marcin Misterski; Tomasz Urbanowicz; Marcin Ligowski; Bartosz Zabicki; Marek Dabrowski; Lukasz Szarpak; Marek Jemielity Journal: J Thorac Dis Date: 2017-11 Impact factor: 2.895
Authors: Piotr Buczkowski; Mateusz Puslecki; Sebastian Stefaniak; Robert Juszkat; Jerzy Kulesza; Marcin Misterski; Tomasz Urbanowicz; Marcin Ligowski; Bartosz Zabicki; Marek Dabrowski; Lukasz Szarpak; Damian Gorczyca; Marek Jemielity; Bartłomiej Perek Journal: J Thorac Dis Date: 2019-06 Impact factor: 2.895